Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Low-Intensity Focused Ultrasound Targeting the Dorsolateral Prefrontal Cortex for Preventive Treatment of Chronic Migraine

28 settembre 2026 aggiornato da: Zhao Dong, MD, Chinese PLA General Hospital

Efficacy and Safety of Low-Intensity Focused Ultrasound Targeting the Dorsolateral Prefrontal Cortex for Preventive Treatment of Chronic Migraine in Adults: A Randomized, Single-Blind, Sham-Controlled Trial

Chronic migraine is a disabling neurological disorder characterized by frequent headache attacks and significant impairment of quality of life. Low-intensity focused ultrasound (LIFUS) is a non-invasive neuromodulation technique that can precisely target deep brain regions. This study aims to evaluate the efficacy, safety, and tolerability of LIFUS targeting the left dorsolateral prefrontal cortex (DLPFC) for preventive treatment of chronic migraine in adults.

This is a randomized, single-blind, sham-controlled clinical trial. Eligible participants with chronic migraine will be randomly assigned to receive either active LIFUS stimulation targeting the left DLPFC or sham stimulation. Participants will receive 10 stimulation sessions over 2 weeks and will be followed for 3 months after intervention.

The primary outcome is the change in monthly migraine days from baseline to 1 month after intervention. Secondary and exploratory outcomes include headache-related disability, quality of life, psychological assessments, electrophysiological measurements, neuroimaging changes, and safety outcomes.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

36

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

  • Nome: Mingjie Zhang, Doctor
  • Numero di telefono: (+86) 18910276582
  • Email: mjzhangnk@163.com

Luoghi di studio

  • Cina
    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina
        • Chinese People's Liberation Army General Hospital, First Medical Center
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Participants diagnosed with chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), with a history of migraine for at least 12 months before screening.
  • Migraine onset at or before 50 years of age.
  • During the 3 months before screening, participants have headache occurring on at least 15 days per month, with migraine features or migraine-specific treatment on at least 8 days per month.
  • During the baseline prospective electronic headache diary period, participants record at least 8 migraine days and 15 to 27 headache days.
  • Participants are able to comply with electronic headache diary recording requirements, with data recorded for at least 24 of the 28 days during the screening period.
  • Age between 18 and 65 years at screening visit.
  • Participants are willing and able to provide written informed consent and comply with study procedures.

Exclusion Criteria:

  • History of epilepsy, brain tumor, or traumatic brain injury.
  • History of transcranial magnetic stimulation, transcranial direct current stimulation, or electroconvulsive therapy within the past 3 months.
  • Presence of MRI-incompatible metallic implants, including but not limited to vascular stents, cardiac pacemakers, or ventriculoperitoneal shunts.
  • Clinically significant comorbid chronic pain conditions, such as fibromyalgia, chronic low back pain, or complex regional pain syndrome.
  • Diagnosis of acute or active temporomandibular disorder.
  • History or diagnosis of other primary headache disorders, including chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or atypical migraine subtypes.
  • Use of opioid-containing analgesics for more than 4 days within 1 month before baseline or during baseline period.
  • Use of any migraine preventive medication within 1 month prior to screening.
  • Use of devices or surgical interventions for migraine treatment within 1 month before baseline, including transcranial magnetic stimulation, greater occipital nerve block, or invasive/non-invasive neuromodulation procedures.
  • History of malignant tumors within the past 5 years, except adequately treated localized basal cell carcinoma or carcinoma in situ of the cervix.
  • History of severe psychiatric disorders, including schizophrenia, other psychotic disorders, bipolar disorder, obsessive-compulsive disorder, or post-traumatic stress disorder.
  • Severe anxiety, depression, or manic symptoms according to predefined scale thresholds (SAS, SDS, and BRMS).
  • Significant risk of self-harm or harm to others based on the Columbia Suicide Severity Rating Scale (C-SSRS) assessment or investigator judgment.
  • History of myocardial infarction, stroke, transient ischemic attack, unstable angina, coronary artery bypass surgery, or other revascularization procedures within 12 months before screening.
  • Pregnancy or breastfeeding.
  • Claustrophobia or inability to undergo MRI examination.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: DLPFC-LIFUS
Dispositivo: Low-Intensity Focused Ultrasound Stimulation

Participants receive active low-intensity focused ultrasound stimulation targeting the left dorsolateral prefrontal cortex (DLPFC) for preventive treatment of chronic migraine.
Comparatore fittizio: DLPFC-Sham
Dispositivo: Sham Low-Intensity Focused Ultrasound Stimulation

Participants undergo sham stimulation procedures with identical positioning, coupling, and treatment duration as the active stimulation group, but without effective ultrasound output.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Monthly Migraine Days
Lasso di tempo: Baseline and 1 month after intervention

Change in monthly migraine days from baseline after intervention.
Baseline and 1 month after intervention

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Acute Headache Medication Days
Lasso di tempo: Baseline and 1 month after intervention

Change in the number of days using acute headache medications from baseline to 1 month after intervention.
Baseline and 1 month after intervention
50% Responder Rate Based on Monthly Migraine Days
Lasso di tempo: 1 month after intervention

Proportion of participants achieving at least 50% reduction in monthly migraine days compared with baseline.
1 month after intervention
75% Responder Rate Based on Monthly Migraine Days
Lasso di tempo: 1 month after intervention

Proportion of participants achieving at least 75% reduction in monthly migraine days compared with baseline.
1 month after intervention
Change in Moderate/Severe Headache Days
Lasso di tempo: Baseline and 1 month after intervention

Change in the number of moderate or severe headache days from baseline to 1 month after intervention.
Baseline and 1 month after intervention
Change in Visual Analog Scale (VAS) Score for Headache Intensity
Lasso di tempo: Immediately after each intervention session to 1 month after intervention

Headache intensity is assessed using the Visual Analog Scale (VAS). Scores range from 0 to 10, with higher scores indicating greater headache intensity.
Immediately after each intervention session to 1 month after intervention
Change in Most Bothersome Migraine Symptom (MBS) Improvement Score
Lasso di tempo: Immediately after intervention and 1 month after intervention

Participants identify their most bothersome migraine-associated symptom at baseline from nausea, vomiting, photophobia, or phonophobia. The same symptom is assessed during follow-up using a 7-point patient-reported improvement scale ranging from very much improved to very much worse.
Immediately after intervention and 1 month after intervention
Change in monthly Migraine Disability Assessment (mMIDAS) Score
Lasso di tempo: Baseline, immediately after intervention, and 1 month after intervention

The monthly Migraine Disability Assessment (mMIDAS) questionnaire assesses migraine-related disability during the previous month. Higher scores indicate greater migraine-related disability.
Baseline, immediately after intervention, and 1 month after intervention
Change in Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) Score
Lasso di tempo: Baseline, immediately after intervention, and 1 month after intervention
Baseline, immediately after intervention, and 1 month after intervention
Change in Headache Impact Test-6 (HIT-6) Score
Lasso di tempo: Baseline, immediately after intervention, and 1 month after intervention

The 6-item Headache Impact Test (HIT-6) assesses the impact of headache on daily functioning. Total scores range from 36 to 78, with higher scores indicating greater headache impact.
Baseline, immediately after intervention, and 1 month after intervention
Patient Global Impression of Change (PGI-C) Score
Lasso di tempo: Immediately after intervention and 1 month after intervention

The Patient Global Impression of Change (PGI-C) is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), with higher scores indicating less favorable perceived change.
Immediately after intervention and 1 month after intervention
Change in Generalized Anxiety Disorder 7-item (GAD-7) Score
Lasso di tempo: Baseline, immediately after intervention, and 1 month after intervention

The Generalized Anxiety Disorder 7-item (GAD-7) scale assesses anxiety symptoms. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.
Baseline, immediately after intervention, and 1 month after intervention
Change in Patient Health Questionnaire-9 (PHQ-9) Score
Lasso di tempo: Baseline, immediately after intervention, and 1 month after intervention

The Patient Health Questionnaire-9 (PHQ-9) assesses depressive symptoms. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity.
Baseline, immediately after intervention, and 1 month after intervention
Incidence of Adverse Events
Lasso di tempo: From baseline through completion of the 3-month follow-up visit

Number and proportion of participants who experience one or more adverse events during the study. All observed and spontaneously reported adverse events will be recorded regardless of their relationship to the study intervention; severity and relatedness will also be assessed.
From baseline through completion of the 3-month follow-up visit
Number of Participants with New Abnormal Findings on T2-Weighted MRI
Lasso di tempo: Baseline and within 24 hours after the final intervention session

Number of participants with new brain parenchymal signal abnormalities, hemorrhage, or edema identified on T2-weighted MRI within 24 hours after the final intervention compared with baseline.
Baseline and within 24 hours after the final intervention session

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Long-term Change in Monthly Acute Headache Medication Days
Lasso di tempo: 2 and 3 months after intervention

Change in the number of days using acute headache medications compared with baseline during extended follow-up
2 and 3 months after intervention
Long-term Migraine Responder Rate (≥50%)
Lasso di tempo: 2 and 3 months after intervention

Proportion of participants achieving at least 50% reduction in monthly migraine days compared with baseline during extended follow-up.
2 and 3 months after intervention
Long-term Change in Moderate/Severe Headache Days
Lasso di tempo: 2 and 3 months after intervention

Change in monthly moderate/severe headache days compared with baseline during extended follow-up.
2 and 3 months after intervention
Long-term Change in Migraine Disability (mMIDAS)
Lasso di tempo: 2 and 3 months after intervention

Change in monthly Migraine Disability Assessment (mMIDAS) score compared with baseline during extended follow-up.
2 and 3 months after intervention
Long-term Change in Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) Score
Lasso di tempo: 2 and 3 months after intervention

Change in migraine-specific quality of life assessed using the MSQ v2.1 questionnaire compared with baseline during extended follow-up.
2 and 3 months after intervention
Long-term Change in Headache Impact Test-6 (HIT-6) Score
Lasso di tempo: 2 and 3 months after intervention

Change in headache-related impact assessed using the HIT-6 questionnaire compared with baseline during extended follow-up.
2 and 3 months after intervention

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Chinese PLA General Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

8 ottobre 2026

Completamento primario (Stimato)

31 dicembre 2027

Completamento dello studio (Stimato)

30 aprile 2028

Date di iscrizione allo studio

Primo inviato

11 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

28 settembre 2026

Primo Inserito (Effettivo)

5 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • S2026-344-01

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi